New radioactive therapy shows promise for tough prostate cancers

NCT ID NCT07441837

First seen Mar 09, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This study tests a new radioactive drug called terbium-161 PSMA in 60 men with advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. The drug targets cancer cells and delivers radiation to kill them. Participants will receive three treatments, six weeks apart, and be monitored for safety and effectiveness over about a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anadolu Sağlık Merkezi

    Istanbul, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ankara University Medical School Dept of Nuclear Medicine

    Ankara, 06590, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

  • Bilkent City Hospital

    Ankara, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Memorial Sisli Hospital

    Istanbul, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.